6108 Stock Overview
An investment holding company, engages in distribution and trading of injection drugs and pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
New Ray Medicine International Holding Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.043 |
| 52 Week High | HK$0.084 |
| 52 Week Low | HK$0.032 |
| Beta | -2.82 |
| 1 Month Change | 0% |
| 3 Month Change | 2.38% |
| 1 Year Change | -14.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.33% |
Recent News & Updates
Recent updates
Lacklustre Performance Is Driving New Ray Medicine International Holding Limited's (HKG:6108) 34% Price Drop
Jan 26
There's Reason For Concern Over New Ray Medicine International Holding Limited's (HKG:6108) Price
Jun 08We're Keeping An Eye On New Ray Medicine International Holding's (HKG:6108) Cash Burn Rate
Mar 29
Shareholder Returns
| 6108 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | 4.9% | 0.2% | 1.5% |
| 1Y | -14.0% | -16.9% | 20.6% |
Return vs Industry: 6108 exceeded the Hong Kong Healthcare industry which returned -16.6% over the past year.
Return vs Market: 6108 underperformed the Hong Kong Market which returned 22.4% over the past year.
Price Volatility
| 6108 volatility | |
|---|---|
| 6108 Average Weekly Movement | 18.4% |
| Healthcare Industry Average Movement | 8.2% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.0% |
Stable Share Price: 6108's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6108's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 23 | Qiuqin Wang | www.newraymedicine.com |
New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of injection drugs and pharmaceutical products in the People’s Republic of China. The company’s pharmaceutical products include injections, capsules, tablets, and other drugs for the treatment of muscular dystrophy, cardiomyopathy, acute and chronic myocardial infraction, angina pectoris, parenteral nutrition, hepatitis and impaired immunity, HBe antiogen-positive, decompensated liver cirrhosis, severe hepatitis, tumor relating hepatitis B and chronic hepatitis C, respiratory tract infections, urinary tract infections, genitourinary system infections, intra-abdominal infections, bone and joint infections, septicemia, catabolism, hypermetabolism, pneumonia, skin and soft tissue infections, pelvic inflammatory, diarrhea and digestive system relevant illness, biliary tract infection, and other infections. It also offers marketing and promotion services of drugs.
New Ray Medicine International Holding Limited Fundamentals Summary
| 6108 fundamental statistics | |
|---|---|
| Market cap | HK$71.89m |
| Earnings (TTM) | -HK$12.90m |
| Revenue (TTM) | HK$35.86m |
2.0x
P/S Ratio-5.6x
P/E RatioIs 6108 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6108 income statement (TTM) | |
|---|---|
| Revenue | HK$35.86m |
| Cost of Revenue | HK$25.45m |
| Gross Profit | HK$10.40m |
| Other Expenses | HK$23.31m |
| Earnings | -HK$12.90m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0077 |
| Gross Margin | 29.02% |
| Net Profit Margin | -35.98% |
| Debt/Equity Ratio | 0% |
How did 6108 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 08:22 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
New Ray Medicine International Holding Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kai Ho Lee | SBI China Capital Financial Services Limited |